{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:58:23Z","timestamp":1788307103882,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"am","delay-in-days":461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["HL158932"],"award-info":[{"award-number":["HL158932"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.beha.2022.101381","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:00:30Z","timestamp":1663038030000},"page":"101381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Vaccine-induced immune thrombotic thrombocytopenia"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-0475","authenticated-orcid":false,"given":"Adam J.","family":"Kanack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.beha.2022.101381_bib1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2022.101381_bib2","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.beha.2022.101381_bib3","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMc2106075","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101381_bib4","doi-asserted-by":"crossref","first-page":"n774","DOI":"10.1136\/bmj.n774","article-title":"Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.beha.2022.101381_bib5","article-title":"Daily briefing: European regulator links AstraZeneca vaccine to rare blood clots","author":"Graham","year":"2021","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.beha.2022.101381_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.15585\/mmwr.mm7017e4","article-title":"Updated recommendations from the advisory committee on immunization practices for use of the janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021","volume":"70","author":"MacNeil","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.beha.2022.101381_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.seminhematol.2022.02.002","article-title":"Epidemiology of VITT","volume":"59","author":"Pai","year":"2022","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.beha.2022.101381_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.beha.2022.101381_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.beha.2022.101381_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00963-7","article-title":"Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran","volume":"11","author":"Babamahmoodi","year":"2021","journal-title":"Sci Rep"},{"issue":"10249","key":"10.1016\/j.beha.2022.101381_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.beha.2022.101381_bib12","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101381_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014588","article-title":"Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT","author":"Kanack","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101381_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2014-06-580894","article-title":"Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis","volume":"125","author":"Padmanabhan","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2022.101381_bib15","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.beha.2022.101381_bib16","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beha.2022.101381_bib17","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2022.101381_bib18","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/STROKEAHA.121.035564","article-title":"American heart association\/American stroke association stroke council L. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia","volume":"52","author":"Furie","year":"2021","journal-title":"Stroke"},{"issue":"21","key":"10.1016\/j.beha.2022.101381_bib19","doi-asserted-by":"crossref","first-page":"e2136","DOI":"10.1212\/WNL.0000000000012896","article-title":"Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis","volume":"97","author":"Palaiodimou","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.beha.2022.101381_bib20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2022.03.034","article-title":"Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a Systematic Review and Meta-Analysis","volume":"119","author":"Kim","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.beha.2022.101381_bib21","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2352-3026(18)30046-2","article-title":"Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study","volume":"5","author":"Dhakal","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7873","key":"10.1016\/j.beha.2022.101381_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2022.101381_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jth.14369","article-title":"Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia","volume":"17","author":"Huynh","year":"2019","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.beha.2022.101381_bib24","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT) is mediated by a stereotyped clonotypic antibody","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2022.101381_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.seminhematol.2022.03.002","article-title":"Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"59","author":"Gabarin","year":"2022","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.beha.2022.101381_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.26488","article-title":"Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies","volume":"97","author":"Kanack","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2022.101381_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12707","article-title":"Anti-platelet factor 4 immunoglobulin G levels in vaccine-induced immune thrombocytopenia and thrombosis: persistent positivity through 7 months","volume":"6","author":"Montague","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.beha.2022.101381_bib28","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2021014214","article-title":"Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient","volume":"139","author":"Schonborn","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101381_bib29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014684","article-title":"Natural history of PF4 antibodies in vaccine induced immune thrombocytopenia and thrombosis","author":"Craven","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2022.101381_bib30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2022.101381_bib31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.2021014712","article-title":"Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration","volume":"140","author":"Nicolai","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2022.101381_bib32","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2022.101381_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjh.18245","article-title":"Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers","volume":"198","author":"Petito","year":"2022","journal-title":"Br J Haematol"},{"issue":"49","key":"10.1016\/j.beha.2022.101381_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.beha.2022.101381_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.779453","article-title":"Inflammation and platelet activation after COVID-19 vaccines - possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis","volume":"12","author":"Ostrowski","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2022.101381_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022007766","article-title":"The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia","author":"Bissola","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.beha.2022.101381_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12596","article-title":"Vaccine-induced immune thrombotic thrombocytopenia presenting with normal platelet count","volume":"5","author":"Page","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"10.1016\/j.beha.2022.101381_bib38","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1055\/a-1585-6182","article-title":"Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"121","author":"Gabarin","year":"2021","journal-title":"Thromb Haemostasis"},{"issue":"22","key":"10.1016\/j.beha.2022.101381_bib39","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1182\/bloodadvances.2021005388","article-title":"VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.beha.2022.101381_bib40","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMc2112974","article-title":"Vaccine-induced thrombocytopenia with severe headache","volume":"385","author":"Salih","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101381_bib41","author":"Chen"},{"issue":"8","key":"10.1016\/j.beha.2022.101381_bib42","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood.2020008195","article-title":"A prospective, blinded study of a PF4-dependent assay for HIT diagnosis","volume":"137","author":"Samuelson Bannow","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2022.101381_bib43","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101381_bib44","article-title":"Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany","volume":"12","author":"Thiele","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"10.1016\/j.beha.2022.101381_bib45","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"Platton","year":"2021","journal-title":"J Thromb Haemostasis"},{"issue":"12","key":"10.1016\/j.beha.2022.101381_bib46","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1055\/a-1535-9002","article-title":"PF4-Dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison","volume":"121","author":"Sachs","year":"2021","journal-title":"Thromb Haemostasis"},{"issue":"9","key":"10.1016\/j.beha.2022.101381_bib47","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/jth.15457","article-title":"Laboratory testing for post ChAdOx1 nCOV-19 vaccination VITT: a challenge. Comment on: recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Vercruysse","year":"2021","journal-title":"J Thromb Haemostasis"},{"issue":"8","key":"10.1016\/j.beha.2022.101381_bib48","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/jth.15766","article-title":"Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide","volume":"20","author":"Reilly-Stitt","year":"2022","journal-title":"J Thromb Haemostasis"},{"issue":"3","key":"10.1016\/j.beha.2022.101381_bib49","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.chest.2016.02.641","article-title":"A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia\/thrombosis","volume":"150","author":"Padmanabhan","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.beha.2022.101381_bib50","first-page":"1322","article-title":"A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT","volume":"114","author":"Padmanabhan","year":"2015","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.beha.2022.101381_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022017283","article-title":"Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies","author":"Kanack","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2022.101381_bib52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/trf.15105","article-title":"Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia","volume":"59","author":"Irani","year":"2019","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.beha.2022.101381_bib53","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.beha.2022.101381_bib54","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09537104.2020.1828574","article-title":"Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty","volume":"32","author":"Hwang","year":"2021","journal-title":"Platelets"},{"issue":"5","key":"10.1016\/j.beha.2022.101381_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/jth.14411","article-title":"High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome","volume":"17","author":"Mohanty","year":"2019","journal-title":"J Thromb Haemostasis"},{"issue":"9","key":"10.1016\/j.beha.2022.101381_bib56","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2109465","article-title":"Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Patriquin","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"10.1016\/j.beha.2022.101381_bib57","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S0140-6736(21)00872-2","article-title":"Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"397","author":"Bayas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2022.101381_bib58","article-title":"Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S","author":"Huynh","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.beha.2022.101381_bib59","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.7326\/L21-0244","article-title":"Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine","volume":"174","author":"Sangli","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2022.101381_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.772424","article-title":"Case report: vaccine-induced immune thrombotic thrombocytopenia in a pancreatic cancer patient After vaccination with messenger RNA-1273","volume":"8","author":"Su","year":"2021","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.beha.2022.101381_bib61","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/liv.15242","article-title":"Acute Budd-Chiari syndrome with thrombotic thrombocytopenia after BNT162b2 mRNA vaccination","volume":"42","author":"Sung","year":"2022","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.beha.2022.101381_bib62","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.26542","article-title":"COVID-19 mRNA-1273 vaccine induces production of vaccine-induced immune thrombotic thrombocytopenia antibodies","volume":"97","author":"Padmanabhan","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2022.101381_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2025009","article-title":"Global landscape of COVID-19 vaccination progress: insight from an exploratory data analysis","volume":"18","author":"Dey","year":"2022","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.beha.2022.101381_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2036556","article-title":"VITT with inactivated SARS-CoV-2 vaccine - index case","volume":"18","author":"Devi","year":"2022","journal-title":"Hum Vaccines Immunother"},{"issue":"4","key":"10.1016\/j.beha.2022.101381_bib65","article-title":"Thrombotic thrombocytopenia after Sinopharm BBIBP-CorV COVID-19 vaccination","volume":"6","author":"Hosseinzadeh","year":"2022","journal-title":"Res Prac Thrombosis Haemostasis"},{"issue":"3","key":"10.1016\/j.beha.2022.101381_bib66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"Johansen","year":"2022","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.beha.2022.101381_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26659","article-title":"Human papilloma virus vaccine and VITT antibody induction","author":"Kanack","year":"2022","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.beha.2022.101381_bib68","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.2021015329","article-title":"Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose","volume":"139","author":"Krzywicka","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101381_bib69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc2118507","article-title":"VITT and second doses of covid-19 vaccine","volume":"386","author":"Lacy","year":"2022","journal-title":"N Engl J Med"},{"issue":"10313","key":"10.1016\/j.beha.2022.101381_bib70","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(21)02285-6","article-title":"Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?","volume":"398","author":"Pavord","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2022.101381_bib71","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.seminhematol.2022.03.001","article-title":"Longitudinal aspects of VITT","volume":"59","author":"Schonborn","year":"2022","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2022.101381_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022007753","article-title":"Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT","author":"Abou-Ismail","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.beha.2022.101381_bib73","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:12Z","timestamp":1761498492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692622000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1521692622000366"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2022.101381","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-induced immune thrombotic thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2022.101381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101381"}}